Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients

Lung

Volumn 182, Issue 6, 2004, Pages 369-377

  Beeh, Kai M ^a   Beier, Jutta ^a   Lerch, Claudia ^b   Schulz, Ann K ^b   Buhl, Roland ^b  

^a Institut fur Atemwegsforschung INSAF   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Antiinflammatory drugs; Asthma; COPD; Neutrophils; Phosphodiesterase inhibitors; Piclamilast

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LUMINOL; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PREDNISOLONE; THEOPHYLLINE; 3 (CYCLOPENTYLOXY) N (3,5 DICHLORO 4 PYRIDYL) 4 METHOXYBENZAMIDE; 3-(CYCLOPENTYLOXY)-N-(3,5-DICHLORO-4-PYRIDYL)-4-METHOXYBENZAMIDE; BENZAMIDE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; ASTHMA; CHEMOLUMINESCENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; RESPIRATORY BURST; SPUTUM CULTURE; CYTOLOGY; FEMALE; MIDDLE AGED; PATHOLOGY; SPUTUM;

ADULT; ASTHMA; BENZAMIDES; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PREDNISOLONE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PYRIDINES; RESPIRATORY BURST; SPUTUM; THEOPHYLLINE;

EID: 17144403788     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-004-2518-z     Document Type: Article

References (25)

1. W MacNee 2001 Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy Novartis. Found. Symp. 234 169 185
2. S Teramoto H Kume T Ishii T Matsuse 2002 Production of oxygen radicals by peripheral blood neutrophils is increased in patients with stable asthma and during exacerbations Respiration 69 286
3. VM Keatings A Jatakanon YM Worsdell PJ Barnes 1997 Effects of inhaled and oral glucocorticosteroids on inflammatory indices in asthma and COPD Am. J. Respir. Crit. Care Med. 155 542 548
4. P Reid 2002 Roflumilast Altana Pharma Curr. Opin. Investig. Drugs 3 1165 1170
5. G Sturton M Fitzgerald 2002 Phosphodiesterase 4 inhibitors for the treatment of COPD Chest 121 192S 196S
6. A Hatzelmann C Schudt 2001 Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro J. Pharmacol Exp. Ther. 297 267 279
7. DS Bundschuh M Eltze J Barsig L Wollin A Hatzelmann R Beume 2001 In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor J. Pharmacol. Exp. Ther. 297 280 290
8. M Profita G Chiappara F Mirabella R Di Giorgi L Chimenti G Costanzo L Riccobono V Bellia J Bousquet AM Vignola 2003 Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD Thorax 58 573 579
9. JA Karlsson J Souness S Webber K Pollock D Raeburn 1995 Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP 73401 Int. Arch. Allergy Immunol. 107 425 426
10. Thoracic Society 2000 Guidelines for methacholine and exercise challenge testing 1999 Am. J. Respir. Crit. Care Med. 161 309 320
11. RA Pauwels AS Buist PMA Calverley CR Jenkins SS Kurd 2001 Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary Am. J. Respir. Crit. Care Med. 163 1256 1276
12. E Pizzichini MMM Pizzichini A Efthimiadis S Evans MM Morris D Squillace GJ Gleich J Dolovich FE Hargreave 1996 Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements Am. J. Respir. Crit. Care Med. 154 308 317
13. C Dahlgren A Karlsson 1999 Respiratory burst in human neutrophils J. Immunol. Methods 232 3 14
14. SP Crouch R Kozlowski KJ Slater J Fletcher 1993 The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity J. Immunol. Methods 160 81 88
15. Y Sibille HY Reynolds 1990 Macrophages and polymorphonuclear neutrophils in lung defense and injury Am. Rev. Respir. Dis. 141 471 501
16. N Alexis J Soukup A Ghio S Becker 2000 Sputum phagocytes from healthy individuals are functional and activated: a flow cytometric comparison with cells in bronchoalveolar lavage and peripheral blood Clin. Immunol. 97 21 32
17. M Kraft J Pak L Borish RJ Martin 1996 Theophylline's effect on neutrophil function and the late asthmatic response J. Allergy Clin. Immunol. 98 251 257
18. G Dent MA Giembycz KF Rabe B Wolf PJ Barnes H Magnussen 1994 Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition Am. J. Respir. Cell Mol. Biol. 10 565 572
19. RP Schleimer HS Freedland SP Peters KE Brown CP Derse 1989 An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils J. Pharmacol. Exp. Ther. 250 598 605
20. DA Lomas M Ip A Chamba RA Stockley 1991 The effect of in vitro and in vivo dexamethasone on human neutrophil function Agents Actions 33 279 285
21. CM De Castro R de Manhaes Castro A de Fernandes Medeiros A Queiros Santos WT Ferreira e Silva J de Luis Lima 2000 Effect of stress on the production of O(2)(-) in alveolar macrophages J. Neuroimmunol. 108 68 72
22. I Maridonneau-Parini M Errasfa F Russo-Marie 1989 Inhibition of O2- generation by dexamethasone is mimicked by lipocortin I in alveolar macrophages J. Clin. Invest. 83 1936 1940
23. G Cox 1995 Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes J. Immunol. 154 4719 4725
24. D Bredenboeker J Syed S Leichtl F Rathgeb W Wurst 2002 Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Eur. Respir. J. 20 374s
25. CH Crompton J Gubb R Nieman J Edelson O Amit A Bakst JG Ayr JP Creemers G Schultze-Werninghaus C Brambilla NC Barnes 2001 Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study Lancet 358 265 270